Amgen Reports Q3 Revenue of $6.9 Billion, with EVENITY and Blincyto Sales Surging Over 50%

On November 9, Amgen released its Q3 2023 financial report, which showed stable growth in Amgen's Q3 performance.

Total revenue in the third quarter reached $6.9 billion, a year-over-year increase of 4%, with product sales volume growing by 11% year-over-year. Non-GAAP earnings per share were $4.96, a year-over-year increase of 6%.

Fulfill the Mission of Serving Patients

• Strong global demand for Amgen's drugs drove product sales volume growth of 11%, marking the fourth consecutive quarter of double-digit sales volume growth.

  
  

• Seven drugs achieved record-high quarterly sales, with EVENITY and Prolia showing sales growth of over 50%.

Advance Innovative Product Pipeline

• In the third quarter, two of Amgen's drugs were granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA): Tarlatamab for the treatment of small cell lung cancer, and Belantamab for the treatment of acute lymphoblastic leukemia.

• New data from the Phase 2 clinical trial of Olpasiran show that lipoprotein(a) levels remain reduced approximately one year after the last dose.

Practice Corporate Social Responsibility

Amgen was named one of the "World's Best Companies" by Time magazine and made it to the Forbes list of "World's Best Employers."

Editor: Muyan

Disclaimer: This article is a reprint from Yaozhi.com. The images and text are the property of the original author. The purpose of the reprint is to convey more information and does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.